Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedifastFRA:MDF -1.64%67 EV-to-EBIT is 2.28 as of Jul. 17, 2026, which is 80% below its 10-year median of 11.41. GuruFocus rates FRA:MDF with a GF Score™ of 67/100 and a GF Value™ of €7.37. The stock has 2 warning signs investors should review. Among 70 Personal Services companies, Medifast ranks better than 88.57% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medifast's Enterprise Value for the quarter that ended in Mar. 2026 was €-40.7 Mil.
Medifast's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medifast EV-to-EBIT Related Terms
Medifast EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Medifast's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Personal Services subindustry, Medifast's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medifast EV-to-EBIT vs Personal Services Industry
For the Personal Services industry and Consumer Cyclical sector, Medifast's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medifast's EV-to-EBIT falls into.
Medifast's current Enterprise Value is €-31.7 Mil.
Medifast's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medifast (FRA:MDF) has a EV-to-EBIT of 2.28 as of Jul. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medifast and its competitors. This is 80% below median its historical median of 11.41. According to the industry distribution chart, Medifast ranks #8 out of 70 companies in the Personal Services industry, placing it in the top 11.4%.
Is Medifast's EV-to-EBIT too high?
Medifast's current EV-to-EBIT of 2.28 is 80% below median its 10-year median of 11.41. The Personal Services industry median EV-to-EBIT is 13.27. Medifast's value of 2.28 is 82.8% below this industry median. Based on the distribution chart, Medifast ranks #8 out of 70 companies in the Personal Services industry, which is in the top quartile — a strong position relative to peers. Overall, Medifast has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Medifast's EV-to-EBIT compare to RGS and EVTK?
According to the Personal Services industry distribution chart, Medifast ranks #8 out of 70 companies for EV-to-EBIT. This places Medifast in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 13.27. Medifast's value of 2.28 is 82.8% below this benchmark. While the company's 10-year median is 11.41 vs. the industry median of 13.27, Medifast has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Personal Services company?
The median EV-to-EBIT among Personal Services companies is 13.27, based on 70 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medifast's current EV-to-EBIT of 2.28 is 82.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medifast and its competitors. For the Personal Services industry, the median EV-to-EBIT is 13.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medifast's current EV-to-EBIT is 2.28, which is 80% below median its own 10-year median of 11.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medifast stock overvalued right now?
Medifast (FRA:MDF) has a current EV-to-EBIT of 2.28. The stock's GF Value™ is €7.37, compared to a current price of €9.01 — trading 22.3% above its estimated fair value. The current EV-to-EBIT is 2.28, which is 80% below median its 10-year median of 11.41 and 82.8% below the Personal Services industry median of 13.27. Medifast's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medifast (FRA:MDF), the current EV-to-EBIT is 2.28 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medifast (FRA:MDF) Overvalued in 2026?
Based on GuruFocus' analysis, Medifast stock appears to be overvalued.
The current stock price of €9.01 is trading 22.3% above its estimated GF Value™ of €7.37.
Key valuation signals for FRA:MDF:
EV-to-EBIT: 2.28 (80% below median its 10-year median of 11.41)
GF Value™: €7.37 vs. price of €9.01 (22.3% above fair value)
Industry Position: 82.8% below the Personal Services median (#8 of 70)
No single metric tells the full story. See the FRA:MDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
67GF Score
Get the complete analysis for FRA:MDF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MDF has been successfully added to your 
